Are Peptides Legal? The Complete 2026 Country-by-Country Guide

---

Table of Contents

1. The Short Answer
2. United States — The Full Picture
3. The FDA Category 2 List Explained
4. What Is a 503A vs 503B Pharmacy?
5. The 2026 PCAC Review — What's Happening Now
6. Research Chemicals: The Grey Area
7. European Union
8. United Kingdom
9. Canada
10. Australia
11. Peptide Legality by Compound
12. Peptides and Sports: WADA Status
13. Frequently Asked Questions
14. Sources

---

The Short Answer

There is no single answer to "are peptides legal?" because the legal status depends on three variables:

Which peptide? Insulin, semaglutide, and tirzepatide are FDA-approved drugs with clear legal pathways. BPC-157 and TB-500 occupy a more complex regulatory position. Each compound has its own status.

Which country? The US, EU, UK, Canada, and Australia all regulate peptides differently. A peptide that's freely available in one jurisdiction may require a prescription or be outright banned in another.

For what purpose? A peptide sold as a "research chemical" for laboratory use occupies a different legal category than one prescribed by a physician for therapeutic use. The intended use determines which regulations apply.

With those caveats understood, here's the detailed breakdown.

---

United States — The Full Picture

The US regulatory landscape for peptides has been in significant flux since 2023. Here's what happened and where things stand as of October 4, 2026.

The Pre-2023 Landscape

Before 2023, many therapeutic peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, and others — were available through licensed compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act¹. Physicians prescribed them, and pharmacies compounded them for individual patients. That was the main route to peptide therapy in the US.

Separately, research-grade peptides labeled "not for human consumption" were (and still are) sold by various suppliers for laboratory and research purposes. These products exist in a legal grey area — they're not regulated as drugs, but their use for personal therapeutic purposes is not explicitly authorized either.

The 2023–2024 FDA Enforcement Actions

On September 29, 2023, FDA began placing peptides in Category 2 of its interim policy for bulk drug substances, the group it says raises significant safety risks. Category 2 is not a ban on the molecule. It tells 503A pharmacies that FDA may take action if they compound with it. Most of the peptides clinics prescribed ended up there, among them:

• BPC-157
• Thymosin beta-4 fragment (the sequence sold as TB-500)
• CJC-1295
• Ipamorelin
• Thymosin alpha-1
• AOD-9604
• Selank
• Dihexa
• KPV
• and several others

FDA's stated concerns were specific: for most of these injectable peptides, a risk of immune reactions from aggregation and peptide-related impurities and difficulty characterizing the active ingredient, and for some, such as dihexa and KPV, no human exposure data at all (FDA's Category 2 page, content current as of April 22, 2026).

What changed in 2026. The nominators withdrew those nominations. FDA's page now lists 17 substances, almost all of them peptides, as previously in Category 2 and withdrawn, and FDA's 503A category list, updated May 14, 2026, names none of them in any category. Withdrawal is not approval. A 503A pharmacy can compound from a bulk substance only if it has a USP monograph, is part of an approved drug, is on the 503A bulks list, or sits in Category 1 while FDA evaluates it, and these peptides meet none of those tests. As of October 4, 2026, the answer for them is still no.

Among the compounds our tracker follows, these remain in Category 2 (FDA, current as of April 22, 2026): MK-677 (ibutamoren) for 503A pharmacies and 503B outsourcing facilities; GHRP-2 (pralmorelin), GHRP-6 and ipamorelin for 503B outsourcing facilities only. FDA's 503A list also keeps kisspeptin-10 in Category 2.

Impact on Patients and Providers

The Category 2 designation disrupted access for thousands of patients who had been receiving peptide therapy through licensed clinics and compounding pharmacies. Clinics that had built their practices around peptide prescribing faced significant business challenges. Some closed; others pivoted to the remaining available compounds.

Clinics that survived the 2023–2025 enforcement period generally did so by working strictly within the compounding pharmacy framework — using licensed physicians, disclosed pharmacies, real bloodwork, and legitimate clinical oversight. Whether compounding reopens for any of these peptides now depends on FDA acting on the committee's July recommendations, and as of October 4, 2026 it has not.

---

The FDA Category 2 List Explained

FDA sorts nominated bulk drug substances into three categories under its interim 503A policy, using these names on its own list (updated May 14, 2026):

• Category 1: under evaluation. Nominated with enough information for FDA to review. While the review runs, FDA says it does not intend to act against pharmacies that compound with them. This is tolerance, not approval. GHK-Cu for non-injectable use is an example: FDA put it back in Category 1 in May 2026.
• Category 2: significant safety risks. FDA has identified safety risks, and pharmacies that compound with these substances risk enforcement.
• Category 3: nominated without adequate support. The nomination lacked the information FDA needs to evaluate it, and the interim policy's tolerance does not extend to it.

A substance can also sit on no list at all, which is where most popular peptides ended up after their nominations were withdrawn in 2026. That is not a loophole. Outside Category 1, the 503A bulks list, a USP monograph or an approved drug, a 503A pharmacy has no lawful basis to compound it.

None of this makes a peptide illegal to possess. These rules close the pharmacy route; the peptide itself is not a controlled substance. The research-chemical market, covered below, operates outside this framework entirely.

What Is a 503A vs 503B Pharmacy?

This distinction matters enormously for understanding peptide access in the US.

Section 503A pharmacies are traditional compounding pharmacies. They prepare custom medications based on individual prescriptions from licensed practitioners. They operate under state pharmacy board oversight and are exempt from certain FDA manufacturing requirements. Most peptide therapy in the US was provided through 503A pharmacies before the 2023 restrictions.

Section 503B outsourcing facilities are larger-scale compounding operations that can produce medications without individual patient prescriptions. They must register with the FDA, follow current Good Manufacturing Practice (cGMP) standards, and submit to FDA inspections. 503B facilities are subject to more rigorous quality controls but can serve a wider market.

503B facilities work under their own rules. They can compound from a bulk substance only if it is on FDA's 503B bulks list, which requires a clinical need, or if the drug is on FDA's shortage list, and FDA keeps a separate 503B Category 2 (FD&C Act section 503B; FDA's Category 2 page, current as of April 22, 2026). Ipamorelin, GHRP-2 and GHRP-6 are in 503B Category 2. For semaglutide, tirzepatide and liraglutide, FDA proposed not to add them to the 503B list; comments closed July 30, 2026, and FDA had published no final decision as of October 4, 2026 (our GLP-1 transition hub tracks it).

---

The 2026 PCAC Review — What's Happening Now

Rewritten September 25, 2026. An earlier version of this section named a different group of peptides as under review and forecast compounding access by mid-2026. Neither happened, and the section has been replaced rather than patched.

The Pharmacy Compounding Advisory Committee (PCAC) advises FDA on which bulk drug substances belong on the 503A Bulks List — the list that lets a licensed pharmacy compound a drug from a substance that has no USP monograph and is not part of an approved drug. The committee recommends; FDA decides, and it can add a substance only through rulemaking.

In April 2026 FDA removed twelve peptides from Category 2, the "significant safety risks" group, after their nominations were withdrawn. Removal did not make any of them eligible for compounding. FDA then put seven of the twelve before the committee on July 23–24, 2026.

The result: the committee recommended six — BPC-157, KPV, TB-500, MOTS-c, semax and epitalon — and rejected emideltide (DSIP). FDA's own staff had proposed adding none of them, and every vote was close. The tallies, and what each side argued, are on our PCAC hub.

What that means today: nothing has changed yet for pharmacies or patients. As of October 4, 2026, FDA has not added any of the six to the 503A Bulks List and has not placed any of them in Category 1, the interim category under which it generally does not act against pharmacies compounding a substance still under evaluation. Until one of those happens, compounding them falls outside the 503A exemption. What FDA has and hasn't done since the vote →

Still to come: a second committee meeting, due before the end of February 2027, will consider the other five — GHK-Cu, melanotan II, LL-37, dihexa acetate and PEG-MGF. FDA has not set a date. CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604 and selank, often discussed alongside these, are on neither agenda.

Research Chemicals: The Grey Area

Alongside the regulated compounding pharmacy pathway, a separate market exists for peptides sold as "research chemicals" or "for laboratory use only — not for human consumption."

This market operates in a legal grey area. The peptides themselves are not controlled substances. They are not scheduled drugs, and federal law aims at selling them for human use rather than at buying them: introducing an unapproved new drug into interstate commerce is prohibited (FD&C Act section 505(a)), and FDA can refuse imported shipments that appear to be unapproved drugs (section 801(a)). However, they are not regulated for human therapeutic use — meaning there are no legal quality standards, no prescription requirements, and no formal oversight of the products being sold.

The practical reality: Many individuals purchase research-grade peptides from online vendors and use them for personal therapeutic purposes. While this is not explicitly authorized by any regulatory framework, it is also not typically prosecuted at the individual consumer level. Law enforcement attention, when it occurs, tends to focus on vendors making therapeutic claims, practicing medicine without a license, or selling adulterated or misbranded products.

Quality concerns are real: Without regulatory oversight, research peptide quality varies dramatically. Some vendors provide batch-specific Certificates of Analysis (COA) from third-party labs, which can show purity and identity if the certificate is genuine and matches the batch. Others provide no testing, questionable COAs, or products that don't match their labels. The burden of quality verification falls entirely on the consumer.

→ Learn how to evaluate peptide quality with our Vendor Evaluation Checklist — including COA criteria.

---

European Union

The framework (as of October 4, 2026). EU law decides what counts as a medicinal product, and none may be placed on the market without a marketing authorisation, granted either EU-wide by the European Commission on the advice of the European Medicines Agency (EMA) or by a national agency (Directive 2001/83/EC, article 6). Enforcement, and borderline calls about whether a product is a medicine, sit with each member state.

Approved peptides. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) hold EU-wide authorisations and are prescription-only.

Unapproved peptides. BPC-157, TB-500, CJC-1295, ipamorelin and the other research peptides hold no EU authorisation. Sold for use in people, they are unauthorised medicines, which member states can seize and prosecute. How hard each country enforces varies, and we have no primary source that ranks them, so we don't.

United Kingdom

Post-Brexit, the UK operates its own regulatory framework through the Medicines and Healthcare products Regulatory Agency (MHRA)⁶.

Approved peptides. Semaglutide and tirzepatide are licensed by the MHRA and prescription-only, through the NHS and private providers.

Unapproved peptides (as of October 4, 2026). BPC-157, TB-500, CJC-1295 and the rest are not controlled drugs, and buying them for your own use is not an offence. Selling or supplying one as a medicine without a licence is, and so is advertising it (Human Medicines Regulations 2012, regulations 46 and 279). The Advertising Standards Authority also polices marketing claims.

Clinics. A UK prescriber can prescribe an unlicensed medicine for an individual patient, and licensed "specials" manufacturers can make it, with the prescriber taking personal responsibility for that choice (regulation 167). That is the lawful clinical route, and it is far narrower than the US compounding market was before 2023.

Canada

Health Canada regulates drugs under the Food and Drugs Act and the Food and Drug Regulations. A new drug needs a Notice of Compliance and a Drug Identification Number before it can be sold (Food and Drug Regulations, C.08.002 and C.01.014).

Approved peptides. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) are approved and prescription-only.

Unapproved peptides (as of October 4, 2026). BPC-157, TB-500, CJC-1295 and similar compounds have no Health Canada authorisation, so selling them as drugs is illegal. They are not listed under the Controlled Drugs and Substances Act. The Canada Border Services Agency can inspect and detain shipments of unauthorised health products.

Australia

Australia regulates medicines through the Therapeutic Goods Administration (TGA)⁴ and schedules them in the Poisons Standard, which the states and territories enforce.

BPC-157 is Schedule 4. In a final decision published May 22, 2024, the TGA's scheduling delegate created a Schedule 4 (prescription-only) entry for BPC-157 in the Poisons Standard and prohibited possession without appropriate authorisation. The decision cited 48 referrals for importation of BPC-157 received by the TGA since July 1, 2022 (TGA, ACMS #43 scheduling decision).

TB-500 is Schedule 4 too. Thymosin beta-4 and TB-500 were added to Schedule 4 and to Appendix D, Part 5 (the possession controls for performance and image enhancing drugs) by a scheduling delegate's final decision of March 17, 2016, as a later TGA scheduling document records (TGA, interim decisions, November 2017, read October 5, 2026). The same document records that growth hormone secretagogues were already a Schedule 4 class entry, noting that ibutamoren (MK-677) was captured by it before getting its own proposed entry.

Other research peptides. Several performance peptides were scheduled earlier. We have not re-verified each of their entries for this update, so check the current Poisons Standard before relying on a specific one (as of October 4, 2026). Separately, importing or supplying therapeutic goods that are not on the Australian Register of Therapeutic Goods is an offence (Therapeutic Goods Act 1989, section 19B).

Approved peptides. Semaglutide and tirzepatide are TGA-approved and prescription-only.

Country by country, with each regulator's position dated and sourced: United Kingdom, European Union, Germany, France, Netherlands, Ireland, Canada, Australia, New Zealand, Japan, Mexico, Brazil, China, Thailand and United Arab Emirates (all country pages).

Peptide Legality by Compound

US and WADA columns are rendered from our regulatory tracker and its public dataset: 503A and 503B categories as FDA lists them (category list updated May 14, 2026; Category 2 page current as of April 22, 2026), re-read September 26, 2026; WADA sections from the 2026 Prohibited List, read in full July 16, 2026. PCAC votes are as reported; FDA has posted no minutes. GHK-Cu for non-injectable use is back in Category 1. EU, UK, Canada and Australia columns say whether a compound holds a marketing authorisation there, as of September 26, 2026; the Australia BPC-157 entry is the TGA's own scheduling decision.

Key: ✅ = Approved/Legal, ⚠️ = Grey area or restricted, S4 = Schedule 4 (Rx required)

→ Check any specific peptide's legal status in our Encyclopedia — each full-tier entry includes a five-jurisdiction legal matrix, updated as regulations change.

---

Peptides and Sports: WADA Status

The World Anti-Doping Agency's Prohibited List binds athletes in sports that follow the World Anti-Doping Code. This is the 2026 List, in force from January 1 to December 31, 2026, as our tracker reads it line by line (checked against the List itself on July 16, 2026):

• Named on the List, prohibited at all times: BPC-157 (S0), TB-500 (S2.3), CJC-1295 (S2.2.4) and ipamorelin (S2.2.4).
• Not named, but caught by S0, the catch-all for substances no government health authority has approved for human use: GHK-Cu.
• Not on the List: semaglutide, tirzepatide and PT-141.

Growth hormone itself and IGF-1 are prohibited too (sections S2.2.3 and S2.3). GLP-1 drugs such as semaglutide and tirzepatide are not on the List. WADA published the 2027 List on September 21, 2026, for use from January 1, 2027; it adds peptides to the examples under S0, as our Wire report explains, so check it before competing next year, and assume any injectable peptide is prohibited until you have confirmed otherwise.

Frequently Asked Questions

Can I buy peptides online legally? In most countries, purchasing research-grade peptides online is not explicitly illegal. However, these products are not regulated for human use. The legality depends on the specific peptide, your country, and the intended use. FDA-approved peptides (semaglutide, tirzepatide) require a prescription in all major jurisdictions.

Is it legal to import peptides from overseas? It depends on the country and the compound. In Australia, BPC-157 is Schedule 4 and possessing it without authorisation is prohibited (TGA decision published May 22, 2024). In the US, FDA can refuse imported shipments that appear to be unapproved drugs (FD&C Act section 801(a)). FDA's position is that importing unapproved drugs for personal use is illegal in most circumstances, and our guide to customs seizures explains what happens when a package is stopped. Elsewhere, customs can detain packages that contain unauthorised medicines.

Will my doctor prescribe peptides? Physicians can prescribe FDA-approved peptides such as semaglutide, tirzepatide and bremelanotide (Vyleesi). For unapproved peptides the compounding route depends on FDA's lists: a pharmacy can use a substance that is in Category 1 or on the 503A bulks list. GHK-Cu for non-injectable use, for example, is back in Category 1, while BPC-157 and the other peptides the PCAC recommended in July stay off-limits until FDA acts (FDA category list, May 14, 2026; status as of October 4, 2026).

Are peptides controlled substances? No. In the US, peptides are not classified as controlled substances under the Controlled Substances Act. They are not in the same regulatory category as narcotics, stimulants, or anabolic steroids. Their regulation falls under the FDA's drug and compounding frameworks, which is a separate legal system.

What happens if I get caught with peptides? In most Western countries, possessing research-grade peptides for personal use does not result in criminal prosecution. The legal risk is primarily on the vendor side — selling peptides with therapeutic claims without approval. Individual possession and use, while not explicitly authorized, is rarely the subject of law enforcement action. Australia is the clear exception for BPC-157, where possession without authorisation is prohibited (as of October 4, 2026).

How will the 2026 PCAC review change things? In July 2026 the committee recommended six peptides (BPC-157, KPV, TB-500, MOTS-c, semax and epitalon) for the 503A Bulks List and rejected emideltide. Nothing changes for pharmacies until FDA acts, and as of October 4, 2026 it has added none of them to the list or to Category 1. CJC-1295, ipamorelin, thymosin alpha-1, AOD-9604 and selank are on neither 2026 PCAC agenda; their nominations were withdrawn. If FDA does add any of the six to the list, which it can do only through rulemaking, licensed pharmacies could compound that peptide on prescription again.

---

Related Tools & Articles

• Peptide Encyclopedia — Full profiles including legal status per compound, with five-jurisdiction legal matrices on full-tier entries
• FAQ: Legal Questions — Additional legal and regulatory questions answered
• Vendor Evaluation Checklist — Objective criteria for evaluating peptide vendor quality and compliance

---

Related Tools & Guides

• Beginner's Guide & Peptide Finder Quiz
• Peptide Glossary
• FAQ Knowledge Base
• Vendor Evaluation Framework

---

Related Articles

• How to Evaluate a Peptide Vendor: A Complete 20-Criterion Framework
• How to Reconstitute Peptides: Step-by-Step Guide
• BPC-157 encyclopedia entry
• Semaglutide vs Tirzepatide: Complete Comparison
• Best Peptides for Fat Loss (2026)

---

Sources

1. FDA. (2024). Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A. fda.gov
2. FDA. (2023). Bulk Drug Substances Used in Compounding Under Section 503A — Category 2 Substances. fda.gov
3. PCAC. (2026). Pharmacy Compounding Advisory Committee Meeting Materials. fda.gov/advisory-committees
4. TGA. (2025). Standard for the Uniform Scheduling of Medicines and Poisons — Schedule 4. legislation.gov.au
5. WADA. (2026). The World Anti-Doping Code International Standard — Prohibited List. wada-ama.org
6. MHRA. (2025). Guidance on the Regulation of Compounded Medicines. gov.uk/mhra
7. Health Canada. (2025). Food and Drug Regulations — Pharmaceutical Product Divisions. canada.ca
8. US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act (categories 1–3). Updated May 14, 2026; read September 26, 2026.
9. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 for 503A and 503B, and withdrawn nominations). Content current as of April 22, 2026; read September 26, 2026.
10. Federal Food, Drug, and Cosmetic Act, sections 503A, 503B, 505(a) and 801(a) (21 U.S.C. 353a, 353b, 355(a), 381(a)).
11. Therapeutic Goods Administration. Notice of final decisions to amend (or not amend) the current Poisons Standard, ACMS #43 (November 2023): BPC-157, Schedule 4 entry and prohibition of possession without authorisation. Published May 22, 2024.
12. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, article 6.
13. The Human Medicines Regulations 2012 (UK), regulations 46, 167 and 279.
14. Food and Drug Regulations (Canada), sections C.01.014 and C.08.002; Therapeutic Goods Act 1989 (Australia), section 19B.

---

Legal Disclaimer: This article provides general educational information about the regulatory landscape for peptides as of April 2026. It does not constitute legal advice. Regulations change frequently, and specific legal questions should be directed to a qualified attorney familiar with pharmaceutical and compounding law in your jurisdiction. Grey Peptides is not responsible for individual decisions regarding peptide acquisition or use.

© 2026 GreyPeptides.com — All rights reserved.